Skip to search formSkip to main contentSkip to account menu

endomirabil

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1981
1981
[Cholecystocholangiography via short-term infusion of iodoxamate (author's transl)].
The cholegraphic agent iodoxamate (Endomirabil) was examined in respect of its contrasting performance and it side effects in the… 
1980
1980
[Quality of roentgenological visualization and tolerance of various intravenous cholegraphic contrast media (author's transl)].
The recently introduced intravenous cholegraphic contrast media produce a greater diagnostic yield in radiological routine thanks… 
1978
1978
[Tolerance and contrast density in intravenous cholangiography and cholecystography using a new contrast medium (author's transl)].
The tolerance and diagnostic usefulness of the new intravenous bile contrast medium Endomirabil were subjected to clinical… 
1977
1977
[A contribution to the rate of side-effects of hepatotropic contrast media. A clinical comparative study of iodoxamate (Endomirabil) and ioglycamid (Bilivistan) (author's transl)].
The new substance Iodoxamate (Endomirabil) is a hepatotropic contrast medium. In a clinical comparative study, the contrast of… 
1977
1977
[Pharmacokinetics and plasma albumen binding of iotroxic acid (Biliscopin), iodoxic acid (Endomirabil) and ioglycamine (Biligram) (author's transl)].
Pharmacokinetic data after injection of the new cholegraphic contrast medium iotroxic acid (Biliscopin) in man are reported and… 
1977
1977
[Influence of radiopaque substance and concentration of contrast media as well as time of infusion on excretion of contrast medium and incidence of side effects (author's transl)].
Two hepatotropic contrast media in 3 different concentrations each are administered to a total of 727 patients for infusion… 
1977
1977
[Injection cholecystography--influence of radiopaque substance and injection time on the excretion of contrast media and incidence of side effects].
In a total of 532 patients, Bilivistan and Endomirabil are compared in cholecystography regarding side effects and visualization… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)